| http://dbpedia.org/ontology/abstract
|
유럽 및 개발도상국 임상 시험 파트너십(EDCTP, European and … 유럽 및 개발도상국 임상 시험 파트너십(EDCTP, European and Developing Countries Clinical Trials Partnership)은 유럽 연합과 노르웨이, 스위스와 개발도상국, 기타 기부국 및 제약 회사들이 맺은 파트너십으로, 후천면역결핍증후군과 결핵, 말라리아에 대한 새로운 의약품과 백신을 개발 및 임상시험을 위해 맺어진 파트너십이다. 개발도상국의 빈곤을 촉진하는 질병은 세계적 조치의 필요성을 UN과 G8, 아프리카 연합이 문제의 심각성을 깨닫고 이 프로그램에 2003년에서 2007년까지 6억 유로를 제공을 구상했다. 유럽 집행위원회가 출범한 이후 2001년 5월 15일, 빈곤 감소를 목적으로 둔 후천면역결핍증후군, 말라리아, 결핵에 대한 조치가 가속화되었다. 유럽 집행위원회의 행동 프로그램은 유럽 이사회와 유럽 의회에 의해 채택되었으며, 이후 네덜란드에 본사를 두었다.럽 이사회와 유럽 의회에 의해 채택되었으며, 이후 네덜란드에 본사를 두었다.
, The European and Developing Countries Clin … The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria.[2] The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries. The European Council adopted the Programme for Action: Accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction (COM (2001)96, [3]) on 15 May 2001, following its launch by the European Commission. The Commission proposal was adopted on 16 June 2003 by the Council and the European Parliament.[4] The Programme was to be based on three central pillars: "the impact of existing interventions, the affordability of key pharmaceuticals and trade, and the research and development of specific global public goods."[5] These aims relate specifically with the EU stance on access to essential medicines. [6]ance on access to essential medicines. [6]
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/EDCTP_proposed_expenditure.png?width=300 +
|
| http://dbpedia.org/ontology/wikiPageExternalLink
|
https://www.edctp.org/ +
, https://web.archive.org/web/19981201202700/http:/www.who.int/tdr/ +
, http://ec.europa.eu/research/info/conferences/edctp/edctp_en.html +
, https://web.archive.org/web/20071008192438/http:/www.ipm-microbicides.org/%29 +
, http://ec.europa.eu/comm/trade/issues/global/medecine/index_en.htm +
, http://ec.europa.eu/research/info/conferences/edctp/pdf/background_en.pdf +
, http://europa.eu/eur-lex/pri/en/oj/dat/2003/l_169/l_16920030708en00010005.pdf +
, http://ec.europa.eu/research/info/conferences/edctp/pdf/com-2001-96_final_en.pdf +
, https://web.archive.org/web/20090214212631/http:/www.mmv.org/index.php%29 +
, https://web.archive.org/web/20121012112446/http:/www.gatesfoundation.org/Pages/home.aspx%29 +
, https://web.archive.org/web/20090318151237/http:/www.aeras.org/home/home.php%29 +
|
| http://dbpedia.org/ontology/wikiPageID
|
3151160
|
| http://dbpedia.org/ontology/wikiPageLength
|
6107
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1121980404
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Bill_&_Melinda_Gates_Foundation +
, http://dbpedia.org/resource/Malaria +
, http://dbpedia.org/resource/Category:International_medical_and_health_organizations +
, http://dbpedia.org/resource/African_Union +
, http://dbpedia.org/resource/GlaxoSmithKline +
, http://dbpedia.org/resource/Novo_Nordisk +
, http://dbpedia.org/resource/Medicines_for_Malaria_Venture +
, http://dbpedia.org/resource/European_Organisation_for_Research_and_Treatment_of_Cancer +
, http://dbpedia.org/resource/World_Health_Organization +
, http://dbpedia.org/resource/Bayer +
, http://dbpedia.org/resource/Category:Clinical_research +
, http://dbpedia.org/resource/Sanofi_Pasteur +
, http://dbpedia.org/resource/Clinical_trials +
, http://dbpedia.org/resource/Switzerland +
, http://dbpedia.org/resource/Global_public_good +
, http://dbpedia.org/resource/Charles_Mgone +
, http://dbpedia.org/resource/European_Council +
, http://dbpedia.org/resource/File:EDCTP_proposed_expenditure.png +
, http://dbpedia.org/resource/Novartis_Pharma +
, http://dbpedia.org/resource/International_Partnership_for_Microbicides +
, http://dbpedia.org/resource/Drugs_for_Neglected_Diseases_initiative +
, http://dbpedia.org/resource/Tuberculosis +
, http://dbpedia.org/resource/Wellcome_Trust +
, http://dbpedia.org/resource/Europe +
, http://dbpedia.org/resource/European_Commission +
, http://dbpedia.org/resource/Pharmaceutical_industry +
, http://dbpedia.org/resource/United_Nations +
, http://dbpedia.org/resource/Aeras_Global_TB_Vaccine_Foundation +
, http://dbpedia.org/resource/European_Union +
, http://dbpedia.org/resource/Norway +
, http://dbpedia.org/resource/Vaccine +
, http://dbpedia.org/resource/G8 +
, http://dbpedia.org/resource/European_Parliament +
, http://dbpedia.org/resource/European_Medicines_Agency +
, http://dbpedia.org/resource/HIV +
, http://dbpedia.org/resource/Category:Medical_and_health_organisations_based_in_the_Netherlands +
, http://dbpedia.org/resource/Category:National_agencies_for_drug_regulation +
, http://dbpedia.org/resource/TB_Alliance +
, http://dbpedia.org/resource/Pascoal_Mocumbi +
, http://dbpedia.org/resource/Essential_medicines +
, http://dbpedia.org/resource/Sanofi-Aventis +
|
| http://dbpedia.org/property/bot
|
InternetArchiveBot
|
| http://dbpedia.org/property/date
|
November 2022
|
| http://dbpedia.org/property/fixAttempted
|
yes
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Citation_needed +
, http://dbpedia.org/resource/Template:No_footnotes +
, http://dbpedia.org/resource/Template:Dead_link +
, http://dbpedia.org/resource/Template:Short_description +
, http://dbpedia.org/resource/Template:Update +
, http://dbpedia.org/resource/Template:Third-party_sources +
, http://dbpedia.org/resource/Template:Multiple_issues +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Clinical_research +
, http://dbpedia.org/resource/Category:International_medical_and_health_organizations +
, http://dbpedia.org/resource/Category:Medical_and_health_organisations_based_in_the_Netherlands +
, http://dbpedia.org/resource/Category:National_agencies_for_drug_regulation +
|
| http://purl.org/linguistics/gold/hypernym
|
http://dbpedia.org/resource/Partnership +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/European_and_Developing_Countries_Clinical_Trials_Partnership?oldid=1121980404&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/EDCTP_proposed_expenditure.png +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/European_and_Developing_Countries_Clinical_Trials_Partnership +
|
| owl:sameAs |
http://ko.dbpedia.org/resource/%EC%9C%A0%EB%9F%BD_%EB%B0%8F_%EA%B0%9C%EB%B0%9C%EB%8F%84%EC%83%81%EA%B5%AD_%EC%9E%84%EC%83%81_%EC%8B%9C%ED%97%98_%ED%8C%8C%ED%8A%B8%EB%84%88%EC%8B%AD +
, http://dbpedia.org/resource/European_and_Developing_Countries_Clinical_Trials_Partnership +
, http://www.wikidata.org/entity/Q5413467 +
, https://global.dbpedia.org/id/4jTLT +
, http://rdf.freebase.com/ns/m.08vqw9 +
|
| rdf:type |
http://dbpedia.org/ontology/Organisation +
|
| rdfs:comment |
유럽 및 개발도상국 임상 시험 파트너십(EDCTP, European and … 유럽 및 개발도상국 임상 시험 파트너십(EDCTP, European and Developing Countries Clinical Trials Partnership)은 유럽 연합과 노르웨이, 스위스와 개발도상국, 기타 기부국 및 제약 회사들이 맺은 파트너십으로, 후천면역결핍증후군과 결핵, 말라리아에 대한 새로운 의약품과 백신을 개발 및 임상시험을 위해 맺어진 파트너십이다. 개발도상국의 빈곤을 촉진하는 질병은 세계적 조치의 필요성을 UN과 G8, 아프리카 연합이 문제의 심각성을 깨닫고 이 프로그램에 2003년에서 2007년까지 6억 유로를 제공을 구상했다. 유럽 집행위원회가 출범한 이후 2001년 5월 15일, 빈곤 감소를 목적으로 둔 후천면역결핍증후군, 말라리아, 결핵에 대한 조치가 가속화되었다. 유럽 집행위원회의 행동 프로그램은 유럽 이사회와 유럽 의회에 의해 채택되었으며, 이후 네덜란드에 본사를 두었다.럽 이사회와 유럽 의회에 의해 채택되었으며, 이후 네덜란드에 본사를 두었다.
, The European and Developing Countries Clin … The European and Developing Countries Clinical Trials Partnership (EDCTP) is a partnership between the European Union (EU), Norway, Switzerland and developing countries and other donors, as well as the pharmaceutical industry, to enable clinical trials and the development of new medicines and vaccines against HIV/AIDS, tuberculosis, and malaria.[2] The need for global action against these diseases in order to promote poverty reduction has been recognised by the United Nations, the G8, and the African Union, and the program envisioned the provision of €600 million for the period 2003–2007 in order to translate medical research results into clinical applications relevant to the needs of developing countries.vant to the needs of developing countries.
|
| rdfs:label |
European and Developing Countries Clinical Trials Partnership
, 유럽 및 개발도상국 임상 시험 파트너십
|
